The objective of the study is to confirm clinical performance and safety of the Nanostim leadless cardiac pacemaker system within its intended use and according to its instructions for use.
Study Type
OBSERVATIONAL
Enrollment
491
Complication Free-rate
A complication is defined as a serious adverse device effect
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Na Homolce Hospital
Prague, Czechia
CHRU Albert Michallon
Grenoble, France
Hopital La Timone
Marseille, France
Nouvelles cliniques Nantaises
Nantes, France
CHRU Hopital de Pontchaillou
Rennes, France
CHU Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Kerckhoff-Klinik gGmbH
Bad Nauheim, Germany
Universitätsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany
Klinikum Bielefeld gGmbH Klinikum-Mitte
Bielefeld, Germany
Herzzentrum Dresden GmbH Universitätsklinik
Dresden, Germany
...and 22 more locations